BeyondSpring Inc. (NasdaqCM: BYSI)
Health Care · Biotechnology · US
$0.72
+0.01% today · -60.4% 1Y
BeyondSpring Inc. (NasdaqCM: BYSI) operates in the Biotechnology industry within the Health Care sector. The company is valued at $29.61M and employs 44 people.
Over the last twelve months the share price has lost 60.4%, trading between 0.67 and 2.44.
Tweenvest scores BeyondSpring Inc. across four factors: quality 23/100. Its strongest factor is quality.
BYSI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $29.61M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.17
- Dividend yield
- —
- Beta (5Y)
- 0.12
- 52-week high
- $2.44
- 52-week low
- $0.67
- Avg volume (3M)
- —
- Shares outstanding
- 41.12M
- Employees
- 44
- Next earnings
- —
About BeyondSpring Inc.
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
- ISIN
- KYG108301006
- Founded
- 2010
- Listed since
- Mar 9, 2017
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.